Concepedia

Edward H. van der Horst

EH

Statistics

Publications

16

Citations

976

H-Index

15

Active since

2004

Affiliations

Max Planck Institute of Biochemistry(Current)

Juvaris BioTherapeutics (United States)

Amgen (United States)

Medigene (Germany)

University of California San Diego

Edward H. van der Horst is an author at Max Planck Institute of Biochemistry specializing in medicine, oncology, and molecular oncology.

ORCID

Publications per year

2004–2024

16

Publications

16

HER3 Is a Determinant for Poor Prognosis in Melanoma

Markus Reschke, Daniela Mihic‐Probst, Edward H. van der Horst et al. · Clinical Cancer Research · 2008 · 166 citations · Full text

, , +17

Antibody–Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs

Christopher R. Behrens, Edward Ha, Lawrence Chinn et al. · Molecular Pharmaceutics · 2015 · 153 citations · Full text

, , +17

Metastatic properties and genomic amplification of the tyrosine kinase gene <i>ACK1</i>

Edward H. van der Horst, Yan Degenhardt, Astrid Strelow et al. · Proceedings of the National Academy of Sciences · 2005 · 145 citations · Full text

, , +17

Antitumor activity of an anti‐<scp>CD</scp>98 antibody

Gregory M. Hayes, Lawrence Chinn, Joseph M. Cantor et al. · International Journal of Cancer · 2014 · 70 citations · Full text

, , +16

Discovery of Fully Human Anti-MET Monoclonal Antibodies with Antitumor Activity against Colon Cancer Tumor Models In Vivo

Edward H. van der Horst, Lawrence Chinn, Min Wang et al. · Neoplasia · 2009 · 62 citations · Full text

, , +17

1–5 of 16